Rising Cancer Incidence Fuels Growth In Supportive Care Products Market: Strengthening the Growth Trajectory of the Cancer Supportive Care Products Market

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Cancer Supportive Care Products Market Through 2025?
The market size for cancer supportive care products has experienced robust growth in the past few years. The market, valued at $21.56 billion in 2024, is projected to reach $22.65 billion by 2025, boasting a compound annual growth rate (CAGR) of 5.1%. The historical growth has been driven by the rise in cancer cases, heightened awareness coupled with education, superior healthcare infrastructure, an aging global population, alongside an increase in awareness and early diagnosis of the disease.

What's the Projected Size of the Global Cancer Supportive Care Products Market by 2029?
The market for cancer supportive care products will likely experience consistent expansion in the forthcoming years, reaching a market value of $27.32 billion in 2029, with a compound annual growth rate (CAGR) of 4.8%. The predicted growth over this forecast period can be credited to an increasing incidence of cancer, more patient-oriented practices, enhanced investment in cancer studies, heightened emphasis on individualized medicine, and increasing rates of cancer survival. The forecast period is expected to witness several key trends, including technological progress, sophisticated drug delivery systems, innovative drug mixes, personalized care, and the emergence of degradable products.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cancer-supportive-care-products-global-market-report

Top Growth Drivers in the Cancer Supportive Care Products Industry: What's Accelerating the Market?
The growth of the cancer supportive care products market is slated to be driven by the escalating occurrence of cancer. The risk of cancer augments with advancing age due to cellular modifications and extended exposure to potential triggers. Factors like smoking, unhealthy diet, physical inactivity, and heavy alcohol intake substantially augment the risk of cancer. Cancer supportive care products are employed to alleviate symptoms, elevate the quality of life, and provide supportive care to patients undergoing treatments, thereby addressing the increasing demand due to the escalating cancer incidences. For instance, the American Cancer Society, a US-based nonprofit organization committed to eradicating cancer, projected in January 2024, that there would be 58,450 instances of oral cavity and pharynx cancer. This prediction indicated a 7.2% surge from the 54,540 cases reported in 2023. Consequently, the cancer supportive care products market is projected to grow, prompted by the rise in cancer incidences.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18529&type=smp

What Trends Will Shape the Cancer Supportive Care Products Market Through 2029 and Beyond?
Leading enterprises in the cancer supportive care products market are prioritizing advances in cancer treatments, such as the targeted radioligand therapy (RLT) approach, to increase the effectiveness of treatment, decrease side effects, and enhance patient outcomes overall. The targeted radioligand therapy (RLT) system employs radiolabeled molecules that explicitly bind to markers on cancer cells, delivering localized radiation and selectively destroying cancer cells while preserving healthy tissue. For example, in May 2022, the US Food and Drug Administration (FDA) gave Novartis AG, a pharmaceutical corporation based in Switzerland, approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to be used in the treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has continued to spread after previous treatments. Pluvicto, the first FDA-approved targeted radioligand therapy (RLT) for eligible mCRPC patients, merges a targeting ligand with a therapeutic radioisotope. The FDA also gave approval to Locametz (gallium Ga 68 gozetotide injection), utilized in PET scans in order to identify PSMA-positive lesions, aiding in detecting the spread of cancer and determining patient suitability for Pluvicto therapy.

What Are the Main Segments in the Cancer Supportive Care Products Market?
The cancer supportive care products market covered in this report is segmented -

1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs, Anti-Infective, Anti-Emetics, Monoclonal Antibodies, Erythropoietin Stimulating Agents, Opioid Analgesics, Bisphosphonates, Granulocyte Colony Stimulating Factor
2) By Indication: Lung Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Leukemia, ovary* Cancer, Melanoma Cancer, Other Indications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Compounding Pharmacies

Subsegments
1) By Nonsteroidal Anti-Inflammatory Drugs (Nsaids): Ibuprofen, Aspirin, Naproxen
2) By Anti-Infective: Antibiotics, Antifungal Drugs, Antiviral Drugs
3) By Anti-Emetics: 5-Ht3 Antagonists (Ondansetron), Nk1 Antagonists (Aprepitant), Corticosteroids (Dexamethasone)
4) By Monoclonal Antibodies: Rituximab, Trastuzumab, Bevacizumab
5) By Erythropoietin Stimulating Agents: Epoetin Alfa, Darbepoetin Alfa
6) By Opioid Analgesics: Morphine, Fentanyl, Oxycodone
7) By Bisphosphonates: Zoledronic Acid, Pamidronate, Ibandronate
8) By Granulocyte Colony Stimulating Factor: Filgrastim, Pegfilgrastim

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=18529&type=smp

Which Top Companies are Driving Growth in the Cancer Supportive Care Products Market?
Major companies operating in the cancer supportive care products market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Becton dic*kinson and Company, Teva Pharmaceutical Industries Limited, Baxter International Inc., Daiichi Sankyo Company Limited, Agilent Technologies Inc., Hologic Inc., Illumina Inc., Kyowa Hakko Kirin Co. Ltd., QIAGEN N.V., Exelixis Inc., Fagron Group B.V., Tessa Therapeutics Pte Ltd., Mirati Therapeutics Inc., APR Applied Pharma Science Research S.A., Acacia Pharma Ltd., Arquer Diagnostics Ltd.

Which Regions Will Dominate the Cancer Supportive Care Products Market Through 2029?
North America was the largest region in the cancer supportive care products market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer supportive care products market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18529

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.